Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Notorious Pictures SpA
MIL:NPI
|
IT |
|
AF Global Ltd
SGX:L38
|
SG |
|
C
|
Chipotle Mexican Grill Inc
BMV:CMG
|
US |
|
Z
|
Zhejiang Hisun Biomaterials Co Ltd
SSE:688203
|
CN |
|
B
|
Blue Owl Capital Corporation III
NYSE:OBDE
|
US |
|
Want Want China Holdings Ltd
HKEX:151
|
CN |
|
X
|
Xin Yuan Enterprises Group Ltd
HKEX:1748
|
CN |
|
Apollo Tourism & Leisure Ltd
ASX:ATL
|
AU |
|
A
|
Aseed Holdings Co Ltd
TSE:9959
|
JP |
|
T
|
Telcoware Co Ltd
KRX:078000
|
KR |
Brainstorm Cell Therapeutics Inc
Accrued Liabilities
Brainstorm Cell Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
Accrued Liabilities
$981k
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Accrued Liabilities
$450.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
35%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
See Also
What is Brainstorm Cell Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
981k
USD
Based on the financial report for Mar 31, 2025, Brainstorm Cell Therapeutics Inc's Accrued Liabilities amounts to 981k USD.
What is Brainstorm Cell Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-5%
Over the last year, the Accrued Liabilities growth was -20%. The average annual Accrued Liabilities growth rates for Brainstorm Cell Therapeutics Inc have been -17% over the past three years , -17% over the past five years , and -5% over the past ten years .
